YU51302A - Novi tetrahidropiridini, postupak njihovog dobijanja i farmaceutski preparati koji ih sadrže - Google Patents

Novi tetrahidropiridini, postupak njihovog dobijanja i farmaceutski preparati koji ih sadrže

Info

Publication number
YU51302A
YU51302A YU51302A YUP51302A YU51302A YU 51302 A YU51302 A YU 51302A YU 51302 A YU51302 A YU 51302A YU P51302 A YUP51302 A YU P51302A YU 51302 A YU51302 A YU 51302A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical compositions
compositions containing
preparation
containing same
independently represent
Prior art date
Application number
YU51302A
Other languages
English (en)
Inventor
Marco Baroni
Bernard Bourrie
Rosanna Cardamone
Pierre Casellas
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of YU51302A publication Critical patent/YU51302A/sh
Publication of RS50432B publication Critical patent/RS50432B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

Pronalazak se odnosi na jedinjenja formule (I) gde: R1 predstavlja atom vodonika ili halogena, ili grupu CF3; R2 i R3 predstavljaju nezavisno atom vodonika ili metil grupu; n i n1 predstavljaju svakj nezavisno 0 ili 1; *predstavlja položaje vezivanja; A predstavlja N ili CH; X predstavlja atom sumpora ili kiseonika; R4 i R5 predstavljaju nezavisno atom vodonika ili (C1-6)alkil grupu; isto kao na njihove soli ili solvate. Pronalazak se takodje odnosi na postupak za dobijanje pomenutih jedinjenja i farmaceutskih preparata koji ih sadrže.[The invention concerns compounds of formula (I) wherein: R1 represents a hydrogen or halogen atom or a CF3 group; R2 and R3 independently represent a hydrogen atom or a methyl group; n and n' each independently represent 0 or 1;* represents the binding positions; A represents N or CH; X represents a sulphur or oxygen atom; R4 and R5 independently represent a hydrogen atom or a (C1-C6) alkyl group, as well as their salts or solvates. The invention also concerns a method for preparing said compounds and pharmaceutical compositions containing them.
YUP-513/02A 2000-01-06 2000-12-29 Novi tetrahidropiridini, postupak njihovog dobijanja i farmaceutski preparati koji ih sadrže RS50432B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0000113A FR2803593B1 (fr) 2000-01-06 2000-01-06 Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
YU51302A true YU51302A (sh) 2005-06-10
RS50432B RS50432B (sr) 2009-12-31

Family

ID=8845654

Country Status (28)

Country Link
US (1) US6689797B2 (sh)
EP (1) EP1248785B1 (sh)
JP (1) JP2004501861A (sh)
KR (1) KR100755103B1 (sh)
CN (1) CN1200939C (sh)
AT (1) ATE297918T1 (sh)
AU (1) AU782650B2 (sh)
BR (1) BR0016921A (sh)
CA (1) CA2395969C (sh)
CZ (1) CZ300658B6 (sh)
DE (1) DE60020885T2 (sh)
EA (1) EA004858B1 (sh)
EE (1) EE04814B1 (sh)
FR (1) FR2803593B1 (sh)
HK (1) HK1050532A1 (sh)
HU (1) HU224815B1 (sh)
IL (1) IL150605A0 (sh)
IS (1) IS2472B (sh)
ME (1) MEP21808A (sh)
MX (1) MXPA02006709A (sh)
NO (1) NO322598B1 (sh)
NZ (1) NZ519723A (sh)
PL (1) PL202761B1 (sh)
RS (1) RS50432B (sh)
SK (1) SK285557B6 (sh)
UA (1) UA72017C2 (sh)
WO (1) WO2001049684A1 (sh)
ZA (1) ZA200205223B (sh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271554T1 (de) * 1999-10-22 2004-08-15 Sanofi Synthelabo Phenyl- und pyridyl-tetrahydro-pyridine mit tnf inhibitorischer wirkung
FR2831166B1 (fr) * 2001-10-18 2004-02-27 Sanofi Synthelabo Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
JP5550352B2 (ja) * 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
US11129746B2 (en) 2010-06-23 2021-09-28 Dental Choice Holdings Llc Method and oral appliance for improving air intake and reducing bruxism
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
US11795148B2 (en) 2017-12-12 2023-10-24 Queen's University At Kingston Compounds and methods for inhibiting CYP26 enzymes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2060816C3 (de) * 1970-12-10 1980-09-04 Merck Patent Gmbh, 6100 Darmstadt 4-Phenylpiperidinderivate Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen enthaltend diese Verbindungen
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
GB9604036D0 (en) * 1996-02-26 1996-04-24 Merck Sharp & Dohme Therapeutic agents
FR2751645B1 (fr) * 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine

Also Published As

Publication number Publication date
AU782650B2 (en) 2005-08-18
WO2001049684A1 (fr) 2001-07-12
PL357082A1 (en) 2004-07-12
US20030083347A1 (en) 2003-05-01
EE04814B1 (et) 2007-04-16
NO20023251D0 (no) 2002-07-04
EP1248785B1 (fr) 2005-06-15
CN1433412A (zh) 2003-07-30
HUP0204394A3 (en) 2005-04-28
FR2803593A1 (fr) 2001-07-13
RS50432B (sr) 2009-12-31
ATE297918T1 (de) 2005-07-15
UA72017C2 (en) 2005-01-17
KR20020063291A (ko) 2002-08-01
CA2395969A1 (en) 2002-07-03
SK285557B6 (sk) 2007-03-01
EP1248785A1 (fr) 2002-10-16
HUP0204394A2 (en) 2003-05-28
EA200200611A1 (ru) 2002-12-26
BR0016921A (pt) 2002-10-15
EE200200382A (et) 2003-12-15
MEP21808A (en) 2010-06-10
CZ20022302A3 (cs) 2002-10-16
US6689797B2 (en) 2004-02-10
FR2803593B1 (fr) 2002-02-15
CZ300658B6 (cs) 2009-07-08
NZ519723A (en) 2005-08-26
NO20023251L (no) 2002-09-06
IS6452A (is) 2002-06-28
DE60020885T2 (de) 2006-05-11
DE60020885D1 (de) 2005-07-21
EA004858B1 (ru) 2004-08-26
SK9622002A3 (en) 2003-03-04
CA2395969C (en) 2009-05-19
HK1050532A1 (en) 2003-06-27
JP2004501861A (ja) 2004-01-22
ZA200205223B (en) 2004-01-26
KR100755103B1 (ko) 2007-09-04
AU3031101A (en) 2001-07-16
IS2472B (is) 2008-12-15
NO322598B1 (no) 2006-10-30
PL202761B1 (pl) 2009-07-31
MXPA02006709A (es) 2002-10-23
HU224815B1 (en) 2006-02-28
IL150605A0 (en) 2003-02-12
CN1200939C (zh) 2005-05-11

Similar Documents

Publication Publication Date Title
IL160304A (en) Compounds and composition for activating peroxisome proliferators-responsive receptor ??
MXPA04000677A (es) Tienopirimidindionas y su uso en modulacion de enfermedades autoinmunes.
EP1254659A4 (en) STABLE EMULSION PREPARATIONS
NZ536734A (en) Spiroindolinepiperidine derivatives
HUP0300922A2 (hu) Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL150650A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
YU65902A (sh) Farmaceutske smeše koje sadrže derivate 3-aminoazetidina, novi derivati i njihovo spravljanje
IL112462A0 (en) Substituted aromatic compounds
YU51302A (sh) Novi tetrahidropiridini, postupak njihovog dobijanja i farmaceutski preparati koji ih sadrže
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
DE69119135D1 (de) Substituierte Pyridinsulfonamidverbindungen, diese enthaltende herbizide Zusammensetzungen und Verfahren zu ihrer Herstellung
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
MXPA04003568A (es) Aralquil-tetrahidro-piridinas su preparacion y composiciones farmaceuticas que contienen las mismas.
UA72934C2 (uk) Феніл- і піридилтетрагідропіридини, що інгібують фактор некрозу пухлин, спосіб їх одержання та фармацевтична композиція
RS20050018A (en) Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors
DK1165543T3 (da) Fremgangsmåde til fremstilling af [S-(R*,S*)]-G(B)-[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinpropansyre og derivater deraf
MY136065A (en) Prodrugs to nmda receptor ligands
NZ504299A (en) 1-aza-2-alkyl-6-aryl-cycloalkane compounds, a process for their preparation and pharmaceutical compositions containing them
ATE502034T1 (de) Thiazolidindionderivate und diese enthaltende pharmazeutische zusammensetzung
GEP20074217B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
TH45494A (th) การเตรียมพิเพอริดิน-4-โอนซึ่งถูกแทนที่